Fernwood Investment Management LLC Has $1.24 Million Stock Holdings in NeoGenomics, Inc. (NASDAQ:NEO)

Fernwood Investment Management LLC decreased its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 2.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 76,500 shares of the medical research company’s stock after selling 1,800 shares during the period. Fernwood Investment Management LLC owned 0.06% of NeoGenomics worth $1,238,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Brown Advisory Inc. increased its stake in shares of NeoGenomics by 25.0% in the third quarter. Brown Advisory Inc. now owns 8,246,202 shares of the medical research company’s stock valued at $101,428,000 after buying an additional 1,651,717 shares during the period. Schroder Investment Management Group grew its stake in NeoGenomics by 26.7% during the third quarter. Schroder Investment Management Group now owns 2,513,307 shares of the medical research company’s stock worth $30,914,000 after purchasing an additional 529,178 shares during the period. Emerald Advisers LLC grew its stake in NeoGenomics by 16.4% during the third quarter. Emerald Advisers LLC now owns 1,927,074 shares of the medical research company’s stock worth $23,703,000 after purchasing an additional 270,855 shares during the period. Emerald Mutual Fund Advisers Trust grew its stake in NeoGenomics by 13.3% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 1,557,895 shares of the medical research company’s stock worth $19,162,000 after purchasing an additional 183,112 shares during the period. Finally, Fred Alger Management LLC grew its stake in NeoGenomics by 36.9% during the third quarter. Fred Alger Management LLC now owns 1,331,700 shares of the medical research company’s stock worth $16,380,000 after purchasing an additional 359,120 shares during the period. Institutional investors and hedge funds own 98.50% of the company’s stock.

NeoGenomics Stock Up 7.6 %

Shares of NEO stock traded up $1.08 during trading hours on Monday, reaching $15.22. The company had a trading volume of 2,380,812 shares, compared to its average volume of 912,010. NeoGenomics, Inc. has a 12 month low of $11.03 and a 12 month high of $21.22. The company has a debt-to-equity ratio of 0.57, a current ratio of 6.20 and a quick ratio of 5.95. The business has a fifty day simple moving average of $15.04 and a 200-day simple moving average of $15.94. The company has a market cap of $1.94 billion, a price-to-earnings ratio of -21.74 and a beta of 1.10.

NeoGenomics (NASDAQ:NEO) last posted its earnings results on Tuesday, February 20th. The medical research company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.05. NeoGenomics had a negative return on equity of 4.13% and a negative net margin of 14.87%. The company had revenue of $155.55 million for the quarter, compared to analyst estimates of $152.90 million. On average, research analysts expect that NeoGenomics, Inc. will post -0.2 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, General Counsel Alicia C. Olivo sold 2,587 shares of NeoGenomics stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $14.96, for a total transaction of $38,701.52. Following the sale, the general counsel now directly owns 34,866 shares in the company, valued at $521,595.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.30% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. The Goldman Sachs Group raised their target price on NeoGenomics from $17.00 to $19.00 and gave the stock a “buy” rating in a research note on Thursday, February 22nd. William Blair reissued an “outperform” rating on shares of NeoGenomics in a research note on Wednesday, February 21st. Needham & Company LLC raised their price objective on NeoGenomics from $21.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, February 21st. Finally, Piper Sandler raised their price objective on NeoGenomics from $18.00 to $20.00 and gave the company an “overweight” rating in a research note on Monday, February 26th. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $19.50.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.